Trastuzumab deruxtecan for HER2-ultralow metastatic breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study is testing a new drug called trastuzumab deruxtecan (also known as T-DXd) in women with advanced breast cancer that is hormone receptor positive and has a very low level of HER2 (called HER2-ultralow). The trial aims to see if this drug can help shrink or slow the growth of the cancer in this specific group of patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced or metastatic breast cancer that cannot be removed with surgery.
- Your cancer is hormone receptor positive (estrogen and/or progesterone positive).
- Your cancer has been tested and found to be HER2-ultralow (a very low level of HER2).
- You have had at least one but no more than two prior hormone therapies for metastatic disease.
- You have had no more than one prior chemotherapy for metastatic disease, and it was not the most recent treatment before progression.
- You have not been previously treated with a HER2-directed therapy or an antibody-drug conjugate containing an exatecan derivative.
- You do not have active brain metastases that are symptomatic or require treatment.
- You do not have a history of interstitial lung disease or pneumonitis that required steroids.
- You have adequate organ function and no unresolved serious side effects from previous treatments.
- You are not pregnant or breastfeeding, and agree to use highly effective contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted antibody-drug medicine (trastuzumab deruxtecan, T-DXd) in people with metastatic breast cancer that is HER2-low or HER2 IHC 0. It may help by treating tumors that haven’t previously received anti-HER2 treatment in the metastatic setting.
This study follows women with advanced breast cancer (metastatic) who have hormone-receptor positive tumors and low HER2 levels, to see how well a new drug called Trastuzumab Deruxtecan works when used in routine clinical care after prior hormone therapy.
This study looks at how people feel (patient-reported outcomes) and their real-world health data while they receive trastuzumab deruxtecan for advanced HER2-positive, HER2-low, or HER2-ultralow breast cancer. It helps researchers understand what outcomes happen outside of tightly controlled clinical trials.
This study looks at how well the drug Enhertu works for patients with HER2-low breast cancer that has spread. If you are already planning to start Enhertu, researchers will collect data from your regular care to learn more about its effectiveness.
This study looks at how well Trastuzumab Deruxtecan (T-DXd) works in Chinese women with breast cancer that has spread. It is for people whose cancer is either HER2-positive or HER2-low and who have already had some treatment.
This study tests how well trastuzumab deruxtecan (T-DXd) works for people with HER2-low breast cancer that has spread. The treatment is given as part of routine care, and the trial uses advanced imaging (PET/CT) to measure response.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.